BLA 761320 · Outlook Therapeutics, Inc.
Lytenava
Bevacizumab-Vikg · Single-Dose · Vascular Endothelial Growth Factor Inhibitor
NovelCDER novel approval, Jul 24, 2026: To treat patients with neovascular (wet) age-related macular degeneration
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 24, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,998
508 Phase 3, 455 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD). LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) ( 1 ).
Mechanism: Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2026 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
- LYTENAVA · BEVACIZUMAB-VIKG 1.25MG (0.05ML of 25MG/ML · VIAL, SINGLE-DOSE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bevacizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerPivotal-lookingCompleted
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteAcademic, hospital or other
NCT00646607 · 3,756 participants · Start Jun 2007 · Primary completion Apr 2013
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin); FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin) · For: Colon Cancer
Sites: Casale Monferrato, Italy; Ancona, Italy; Fabriano, Italy · 111 sites in all
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00112918 · 3,451 participants · Start Dec 2004 · Primary completion Jun 2010
Drug: Bevacizumab; Capecitabine and 3 more · For: Colorectal Cancer
Sites: Los Angeles, California
- Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00975897 · 3,240 participants (planned) · Start Jul 2009 · Primary completion Aug 2010
Drug: bevacizumab; cetuximab and 4 more · For: Colorectal Cancer
Sites: Leeds, United Kingdom; Belfast, United Kingdom; Cardiff, United Kingdom
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00096278 · 2,710 participants · Start Sep 15, 2004 · Primary completion Mar 12, 2009
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 4 more
Sites: Pittsburgh, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, et al. · J Clin Oncol 2014 · Clinical Trial, Phase III, Multicenter Study
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H, Fehrenbacher L, Novotny W, et al. · N Engl J Med 2004 · Clinical Trial, Clinical Trial, Phase III
- Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA, Brady MF, Bookman MA, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL, Wick W, Mason W, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Outlook Therapeutics, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.